标志性牙过度生长突出口腔由于酸的出口腔
Mami Uegami1, Hiroaki Ito1, Tadashi Shiohama2
1Department of Pediatrics, Kameda Medical Center, 929 Higashi-cho, Kamogawa-shi 296-8602, Chiba, Japan.
Diagnostics (Basel, Switzerland)
|January 25, 2025
概括
酸 (VPA) 是一种抗药物,即使长期使用,也会导致牙过度生长. 停止使用VPA导致了快速改善,突出了其在控制这种口服副作用方面的作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 口腔医学是指口腔医学.
- 神经学 神经学
背景情况:
- 药物诱导的牙过度生长是一些抗药物的已知副作用.
- 氨酸通常与牙过度生长有关,而氨酸 (VPA) 很少涉及.
- 这种变异性强调了需要研究针对口服并发症的特定抗药物的必要性.
研究的目的:
- 确定甲 (VPA) 是患有的患者牙过度生长的致病剂.
- 在长期使用VPA时记录牙过度生长的进展.
- 评估减少VPA剂量和停止治疗对牙过度生长的影响.
主要方法:
- 采用了一个案例研究方法.
- 在使用VPA超过10年的患者中,临床观察了牙过度生长.
- 在VPA剂量减少和停止后,监测牙过度生长的变化.
主要成果:
- 患者出现了显著的牙过度生长,这归因于长期使用VPA.
- 在停止使用VPA后,牙过度生长显示出快速改善.
- 这些发现表明,VPA可以导致牙过度生长,与其罕见的关联相反.
结论:
- 甲 (VPA) 可能是药物诱导的牙过度生长的致病剂,即使长期使用.
- 停止使用VPA可以导致牙过度生长的快速解决.
- 这个案例为VPA诱导的牙过度生长的临床管理提供了宝贵的见解.
相关概念视频
Antiepileptic Drugs: GABAergic Pathway Potentiators
316
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
316
Antiepileptic Drugs: Potassium Channel Activators
142
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
142
Tonsillitis II: Management
103
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
103
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
76
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
76
Antiepileptic Drugs: Sodium Channel Blockers
361
Antiepileptic drugs are specialized medications that prevent seizures in individuals diagnosed with epilepsy. These drugs primarily function by blocking the movement of sodium ions through channels in the neuronal membrane, inhibiting the repetitive firing of action potentials often associated with seizures.
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
361
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
221
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
221


